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Summary
Thanks to the rapid advances in laboratory techniques sensitive assays for measurement of cardiac troponin level have 
been recently introduced, and now is possible to determine ten-fold lower concentration of troponin in blood serum 
than the standard method used until now. The blood level of highly sensitive cardiac troponin in hypertensive pa-
tients is higher than in healthy persons, which may indicate increased necrosis or apoptosis of cardiac cells. Elevated 
high-sensitivity cardiac troponin concentration is an important risk factor for future cardiovascular complications 
independent of many co-existing contributing factors. In particular, elevated concentration of this troponin indi-
cates the left ventricular hypertrophy and a tendency to develop heart failure. It has also been shown that elevated 
concentrations of high-sensitivity troponin are more common in non-dipper patients than in those with a normal 
circadian pattern of blood pressure. Few studies so far indicate that currently used antihypertensive therapy only 
slightly lower the increase concentration of those compounds in serum.
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Troponin T and troponin I are proteins present in 
cardiomyocytes. Cardiomyocyte necrosis causes these 
compounds to be released into the bloodstream. The 
concentration of both these troponins in blood se-
rum has been used for a long time in clinical practice 
in diagnosis of myocardial infarction. Their levels, 
0.03 ug/L for troponin T and 0.12–0.4 ug/L for 
troponin I (depending on the method of determina-
tion), indicate a myocardial infarction [1]. Increased 
troponin levels are highly sensitive and relatively 
specific compared to other laboratory parameters. 
Nevertheless, the increase in troponin levels has also 
been observed in sepsis, pulmonary embolism, severe 
heart failure and myocarditis.
Previously used, conventional methods of deter-
mination of troponin levels in blood serum detect 
concentrations of this compound in the blood with 
an accuracy of 0.01 µg/L. Methods allowing ten 
times lower troponin concentrations, down to 0.001 
µg/L, namely 1 ng/L, to be detected have been de-
veloped during this decade. Currently, three phar-
maceutical companies offer commercially available 
high-sensitivity cardiac troponin T testing kits. These 
are Abbott, Erenna and Roche. 
A large meta-analysis by Willeit, including over 
150,000 people, published a year ago showed that 
even troponin concentrations below 10 ng/L are 
of prognostic significance from the point of view 
of the subsequent development of cardiovascular 
diseases [2]. Troponin presence in blood serum 
was found in 80% of studied individuals, the ave-
rage concentration of this compound was 7 ng/L, 
and it did not exceed 14 ng/L in 95% of the par-
ticipants. The high-sensitivity cardiac troponin T 
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method shows significant statistical correlation 
with participant age, systolic blood pressure, body 
mass, diabetes duration, cholesterol concentration, 
smoking, renal failure and concentration of the 
B-type natriuretic peptide (BNP). Ten years of 
observation of the participants also showed that 
high-sensitivity cardiac troponin T determined 
using a high-sensitivity method is a significant risk 
factor of heart failure and ischaemic heart disease, 
as well as of death. 
In 2011, Setsuta published results of a 52-month 
observation of 176 patients with hypertension dia-
gnosed at least 2 years earlier, in which he initially 
determined troponin T concentration in blood se-
rum using a conventional method [3]. No symp-
toms of cardiovascular diseases were observed in any 
of these patients, in particular using electrocardio-
graphic exertion tests and coronarography, which 
excluded chronic coronary heart disease, while echo-
cardiographic examinations excluded hypertrophic 
cardiomyopathy and heart failure. Normal creatinine 
clearance was identified in all studied patients. In 15 
patients, troponin concentration exceeded 0.02 ng/ 
/mL; in other patients the troponin concentration 
was below the detection limit. In patients with in-
creased troponin levels, cardiovascular complications 
occurred already after a year of observation and were 
statistically more frequent (p < 0.00001) at the end 
of the observation period.
High-sensitivity cardiac troponin T in patients 
with newly diagnosed hypertension was studied for 
the first time by Sato et al. in 236 patients with the 
average age of 65.5 years [4]. The average troponin 
concentration was 0.008 ng/mL in 184 patients. 
The concentration was below 0.003 ng/mL in other 
patients. Patient age, NT-proBNP concentration, 
amounts of hypotensive medication used and left 
ventricular hypertrophy determined by electro-
cardiography showed the positive correlation with 
high-sensitive troponin concentration. On the other 
hand, haemoglobin and eGFR concentrations cor-
related negatively. 
Troponin concentration (high-sensitivity cardiac 
troponin T) may also be used as a marker of the in-
creased tendency to developing hypertension in the 
future in previously healthy individuals. Studies by 
McEvoy et al., who determined high-sensitive tropo-
nin concentration in 6,516 participants of the ARIC 
study [5], indicate this fact. The study was initiated 
in 1990–1992 by collecting blood samples for deter-
mination of high-sensitivity cardiac troponin from 
individuals without hypertension and cardiovascular 
disease, and the onset of hypertension was recorded 
over the period of at least 6 to 20 years (19.9 years). 
The initial troponin concentration below 5 ng/L 
was accepted as the reference value. In individuals 
with troponin concentration in the range of 5–8 ng/ 
/mL, the risk of hypertension development was low 
and estimated at 1.16. In individuals with the ini-
tial troponin levels of 9–13 ng/m/L this risk was 
1.29, and it finally increased to 1.31 in individuals 
with troponin concentration above 14 ng/mL (the 
trend significance was p < 0.001). Left ventricular 
hypertrophy determined using electrocardiography 
was also significantly more frequent in individuals 
with high-sensitivity cardiac troponin T concentra-
tion over 14 ng/mL compared to the troponin level 
below 5 ng/mL (HR 5.19).
An evaluation of high-sensitivity cardiac troponin 
I was presented by Aeschbacher et al. in over 2,000 
young, healthy people in the age group of 25–41 [6]. 
This troponin was detected in 99.5% of the studied 
individuals, and its concentration was 0.98 ng/L 
in males and 0.48 ng/L in females. The concentra-
tion of this troponin in blood serum was divided 
into quartiles. In the lowest quartile, the systolic 
blood pressure was 118 mmHg, 120 mmHg in the 
next quartile, the average pressure was 121 mmHg 
in the third quartile and eventually increased to 
122 mmHg in the last quartile. Diastolic blood pres-
sure had no significant influence on the concen-
tration of the studied troponin. The authors also 
showed a significant correlation between left ventric-
ular hypertrophy determined using electrocardiogra-
phy (the Sokolov method) and the concentration of 
the studied troponin. 
Even the concentration of high-sensitive tropo-
nin in individuals with prehypertension is diffe - 
rent than troponin levels in healthy individuals. This 
was shown by Askin and Yesiltepe who determined 
high-sensitivity cardiac troponin T in 50 individuals 
with blood pressure in the range of 120/80–139/89 
and in 50 healthy individuals of age and sex similar 
to the studied group, with blood pressure below 
120/80 mm Hg [7]. Echocardiography was also per-
formed in all studied individuals. The concentration 
of the studied troponin in the group of patients with 
prehypertension showed to be statistically higher 
than in healthy individuals (p < 0.0001). Troponin 
concentration of 0.55 ng/L proved to be an indicator 
of prehypertension with a sensitivity of 86% and 
specificity of 60% (p < 0.001). The prehypertension 
defined as blood pressure of 120/80–139–89 occurs 
in nearly 30% of the population in our country. In 
many people, prehypertension gradually evolves to 
hypertension over the years. Because of the preva-
lence of prehypertension, results obtained by Askin 
and Yesiltepe are definitely noteworthy. 
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An interesting relationship was also observed by 
Askin et al., between the levels of high-sensitivity 
cardiac troponin and the degree of nocturnal blood 
pressure drop in patients with primary hypertension 
[8]. A 24-hour ambulatory blood pressure monito-
ring (ABPM) was performed in 100 hypertensive in-
dividuals, with 63 of them displaying an appropriate 
drop of blood pressure during the night, and the re-
maining 37 individuals showing the nocturnal blood 
pressure drop lower than 10%. The high-sensitivity 
cardiac troponin levels were significantly higher in 
non-dippers and showed high statistical correlation 
with the disrupted circadian blood pressure rhythm 
(r = 0.747, p > 0.001). Similar observations were 
made by Cayli et al. who studied the blood pressure 
rhythms using the ABPM method in 317 patients 
with new-onset hypertension [9]. The troponin con-
centration was higher in non-dipper patients, and 
the cut-off index was 7.55 ng/L. The authors of this 
study hold an opinion that the sensitivity and spe-
cificity of the method of non-dipper patient identifi-
cation based on troponin measurements is 79% and 
70%, respectively (p < 0.001).
Another author, Hitsumoto, reported a year ago 
that high-sensitivity cardiac troponin T shows signif-
icant correlation with the arterial velocity pulse index 
determined using the commercial device [10]. This 
author showed the presence of high-sensitivity car-
diac troponin in 89% of hypertensive patients, and 
in patients with detectable levels of this troponin, 
the arterial velocity pulse index was 28, while it was 
significantly lower and had a value of 24 in patients 
with undetectable troponin levels. The correlation 
between the high-sensitivity troponin level and the 
arterial velocity pulse index was 0.42, p < 0.001. The 
arterial pulse wave velocity, which is increased in hy-
pertension, is an arterial stiffness measure. Increased 
aortic stiffness may, in turn, accelerate damage to the 
left ventricle of the heart [11]. It is suspected that in-
creased oxidative stress accompanying hypertension 
and increased blood vessel stiffness leads to apoptotic 
death of myocardial cells and heart failure. Studies 
potentially confirming the efficiency of anti-oxida-
tive drugs in patients with increased troponin levels 
in the prevention of cardiovascular complications are 
thus suggested [12]. High-sensitivity cardiac tropo-
nin I level determined in blood serum correlates with 
peripheral blood pressure and central blood pressure 
values, as shown by Suigura et al., who studied these 
relationships in 1,210 participants of yearly health 
checkup program [13]. Central blood pressure and 
the augmentation index were determined in all pa-
tients using the tonometric method. The correlation 
between the central blood pressure and the troponin 
levels was higher in patients with large augmentation 
index values. 
The prognostic significance of high-sensitivity car-
diac troponins was also shown by American authors, 
who studied 11,191 participants of the Atheroscle-
rosis Risk in Communities study [14]. The average 
patient age in the study was 63; the average blood 
pressure was 128/71 mmHg (44% of patients used 
hypotensive medication). The high-sensitivity tropo-
nin levels correlated with the age of the participants, 
NT-proBNP concentration, use of hypotensive drugs 
and indicators of left ventricular hypertrophy in the 
ECG examination. After 12-year observation, the 
number of cardiovascular complications was higher 
with increasing systolic blood pressure, as expect-
ed. However, the number of complications in ev-
ery blood pressure range was the higher, the higher 
was the troponin concentration. Thus, in individuals 
with systolic blood pressure lower than 120 mmHg 
and with troponin levels higher than 14 ng/L, the 
risk of heart failure was 5 times higher than in in-
dividuals in the same blood pressure range and with 
troponin levels below 3 ng/L. The risk of cardiovas-
cular complications in patients with blood pressure 
of 150–160 mmHg and troponin concentration 
< 3 ng/L was very close to the risk in individuals 
with the blood pressure of 120–130 mmHg and 
troponin concentration of 8 ng/L. The authors have 
also shown that individuals with serum troponin 
concentrations higher than 3 ng/L and with systolic 
blood pressure lower than 140 mmHg had a higher 
risk of cardiovascular complications than patients 
with the systolic pressure in the range of 140–159 
and with troponin levels below 3 ng/L. The results of 
this work clearly show that the prognosis of cardio-
vascular complications depends not only on blood 
pressure but also on troponin concentration in blood 
serum [14].
Kaypakli et al. studied high-sensitivity cardiac 
troponin levels in 306 patients with diagnosed hy-
pertension [15]. They showed that this concentra-
tion was higher in the patients with hypertension, 
in whom echocardiography showed left ventric-
ular dysfunction or hypertrophy. A similar study 
was performed by Miao et al. whose observation 
included 537 patients with hypertension and with-
out symptoms of ischaemic heart disease, as well as 
100 healthy individuals of similar age and sex [16]. 
All patients were subjected to a precise echocardio-
graphic examination, lipid and eGFR concentration 
determination. In 78% of patients with hyperten-
sion, troponin T levels higher than 3 pg/mL were 
detected and 30.7% of patients had troponin T level 
above 13 pg/mL, a value significantly higher than in 
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healthy individuals. The authors also showed a grad-
ual significant increase in troponin levels depending 
on remodelling and hypertrophy of the left ventricle 
of the heart. Thus, in patients with hypertension 
and regular geometry of the left ventricle, troponin 
levels were 3.6 pg/mL and gradually increased in 
hypertensive subjects with concentric remodelling, 
concentring hypertrophy and eccentric hypertrophy. 
This correlation was independent of age, gender, 
fasting blood glucose and renal function. 
Hypertension often leads to heart failure and, by 
accelerating atherosclerosis, to myocardial infarc-
tion. In patients with heart failure, the increase in 
high-sensitivity cardiac troponins is also a significant 
prognostic indicator of future cardiovascular com-
plications, as well as of death. This is documented, 
among others, by the work of Graving et al. who 
determined baseline troponin levels in 1,245 pa-
tients aged 60 and older with heart failure [17]. It 
was shown after 3-year observation that in patients 
with baseline troponin concentrations higher than 
14 ng/L heart failure occurred more frequently and 
was more severe, and cardiovascular and overall mor-
tality rates were higher.
In 2018, Aimoi et al. published a meta-analysis 
related to the prognostic value of high-sensitivity 
cardiac troponin in patients with new-onset heart 
failure [18]. This meta-analysis included over 9,000 
patients. Presence of high-sensitivity cardiac tropo-
nin T was proven in all patients, and presence of 
troponin I in 209 studied individuals. It has been 
shown that troponin T concentration is a statistically 
significant and independent risk factor of hospitaliza-
tion related to heart failure and cardiovascular death. 
The threshold level of troponin T above which this 
risk increased was 18 ng/L.
Chronic ischaemic heart disease, caused, among 
others, by hypertension, is also characterised by in-
creased troponin levels in blood serum. The me-
dian high-sensitive cardiac troponin concentration in 
1,050 patients with chronic ischaemic heart disease 
was 10.9 ng/L in a study by Koening et al. [19]. 
During an 8-year observation, 14.3% of patients dis-
played secondary cardiovascular complications, and 
their emergence showed the statistical correlation 
with the initial troponin concentration (HR = 2.83). 
Troponin T is a protein binding tropomyosin, 
while troponin I is an actin-binding protein and 
inhibits actin contact with myosin. Six to eight per-
cent of troponins are present as free troponins in cel-
lular cytoplasm. Troponin presence in blood serum 
is considered as a heart damage indicator [20]. It is 
suspected that apoptotic death of myocardial cells is 
caused by increased load, especially in hypertension, 
increased activity of the renin-angiotensin-aldoste-
rone system and activation of the sympathetic ner-
vous system, which may contribute to necrosis or 
increased permeability of cardiomyocyte cell mem-
branes [21]. This is suggested by observations, which 
have shown significant relationships between blood 
troponin levels and the aforementioned factors [22]. 
Other authors suspect that oxidative stress, hypoxia 
and inflammatory cytokines are factors facilitating 
the apoptotic death of heart cells [23]. Thorough 
understanding of these factors accelerating apoptosis 
should enable development of new drugs inhibiting 
this process [23, 24]. 
Very few studies related to the influence of therapy 
on troponin levels have been published so far. It re-
mains unknown whether lifestyle changes of healthy 
people with increased troponin concentrations may 
inhibit the further increase in the level of this com-
pound in blood serum. The influence of hypoten-
sive therapy on the level of high-sensitivity cardiac 
troponin was studied by Hoshide et al. [25] in 78 
patients with hypertension. Half of these patients 
were treated with losartan and hydrochlorothiazide 
for 8 weeks, while the other half of the patients were 
treated with amlodipine. Blood pressure in both pa-
tient groups, evaluated using the ABPM method, 
decreased significantly. Troponin levels in the group 
treated with amlodipine decreased significantly 
(p < 0.05), while it remained constant in the group treat-
ed with losartan and hydrochlorothiazide. These re-
sults are confirmed by previous experimental studies 
in which hypotensive therapy applied to rats, using 
inhibitors of angiotensin convertase and beta-block-
ers, produced an increment of apoptosis in parallel 
to cardiac hypertrophy regression whereas therapy 
using diuretics and hydralazine did not have any im-
pact on the extent of apoptotic death of myocardial 
cells [23]. The impact of hypotensive therapy on the 
concentration of troponin I in the biggest patient 
group was described by Jagodziński et al. [26]. This 
study included 481 patients divided into two treat-
ment groups, with the first one receiving a 6-month 
telmisartan therapy using a dose 80 mg with 5 mg 
of amlodipine, while the other half of the patients 
were treated with olmesartan using a dose of 40 mg 
with 12.5 mg of hydrochlorothiazide. Blood pres-
sure decreased significantly from 135/85 to 122/ 
/75 mmHg in both patient groups. In the group 
using telmisartan/amlodipine, the levels of troponin 
I decreased from 4.6 to 4.0 ng/L (p < 0.001), while 
in the olmesartan/hydrochlorothiazide sub-group 
a decrease from 4.7 to 4.4 ng/L (p < 0.001) was ob-
served. At the same time, a comparable decrease in 
the BNP concentration was observed in both groups. 
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Tunerir et al. obtained promising results, in 
double-blind trial in which they administered 
trimetazidine 60 mg/day, orally, for three weeks be-
fore a CABG surgery [27]. The preoperative TnT 
concentration ranged from 0 to 0.39 ng/mL. Then, 
the concentration of this troponin was measured 
5 minutes after the surgery, as well as after 12, 24 and 
48 hours. The troponin concentration in blood se-
rum was significantly statistically lower (p < 0.001) 
in all studied periods. Italian researchers also ob-
served positive results of trimetazidine therapy. After 
a 6-month administration of this drug to a patient 
with chronic ischaemic heart disease, they observed 
significant improvement in the cardiac stress test 
combined with a significant decrease in troponin 
and BNP concentrations, contrary to the control 
group in which troponin concentration in blood 
serum remained unchanged, and the BNP level in-
creased [28]. The results obtained by the authors 
cited above should be confirmed in future, large 
clinical tests. 
The high-sensitivity cardiac troponin concentra-
tion in patients with hypertension is a novel, valu-
able risk factor related to cardiovascular diseases. 
Future studies shall likely show which hypertension 
treatment strategy is the most favourable in decreas-
ing the elevated troponin levels and whether such 
therapies can decrease the cardiovascular risk in such 
patients.
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